Table 3.
Monocyte-targeting therapeutic approaches for SLE and RA in humans and mice
| Ref. | |
|---|---|
| Human SLE | |
| Removal by cytapheresis | (64) |
| Murine lupus models | |
| Migration inhibition by anti-MCP-1 gene therapy in MRL/lpr mice | (65) |
| Migration inhibition by CX3CL1 antagonist in MRL/lpr mice | (66) |
| CSF1R signal inhibition by CSF1R inhibitor in MRL/lpr mice | (67) |
| Activation inhibition by soluble FcγR in NZB/NZW F1 mice | (69) |
| Human RA | |
| Treatment with anti-RANKL antibody | (70, 71) |
| Treatment with anti-CX3CL1 antibody | (72) |
| Murine arthritis models | |
| Migration inhibition and depletion by anti-CCR2 antibody in CIA model | (73) |
| CSF1R signal inhibition by anti-CSF1R antibody and by CSF1R inhibitor in CIA, CAIA, K/BxN serum transfer models |
(74) |
| CSF1R signal inhibition by anti-CSF1R antibody in CIA and K/BxN serum transfer models |
(75) |
| Migration inhibition by anti-CX3CL1 antibody in CIA model | (76) |
| Migration inhibition and depletion by anti-CD11b antibody in KO1 mice | (77) |